Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental 'T cell Engager' takes on Hard-to-Treat cancers

NCT ID NCT05359445

Ongoing Disease control Sponsor: Immatics Biotechnologies GmbH Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new drug called IMA401, which helps the body's immune T cells attack cancer cells that have certain markers (MAGE-A4 or MAGE-A8). The study includes about 95 adults with advanced solid tumors that have come back or not responded to other treatments. Some participants will get IMA401 alone, and others will get it combined with the immunotherapy Keytruda, to see if it is safe and shows signs of shrinking tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

IMA401 (a bispecific T cell engaging molecule) and pembrolizumab (Keytruda, a checkpoint inhibitor)

What this could lead to

If this works, it could point toward a new treatment option for certain hard-to-treat solid tumors that express MAGE-A4 or MAGE-A8.

What could go wrong

This is a very early (Phase 1) trial with only 95 participants, so safety and dosing are still being figured out. Many early-stage cancer drugs do not end up working in larger studies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer head and neck squamous cell carcinoma neoplasm non-small cell lung carcinoma Recurrence refractory malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER RECURRENT CANCER REFRACTORY CANCER SOLID TUMOR, ADULT

Contacts and locations

Locations

  • Charité Universitaetsmedizin Berlin KöR, Klinik fuer Haematologie und Onkologie

    Berlin, 12203, Germany

  • Goethe Universitaetsklinikum Frankfurt AöR, Medizinische Klinik II

    Frankfurt am Main, Hesse, 60590, Germany

  • Klinikum Chemnitz gGmbH, Klinik für Innere Medizin III

    Chemnitz, Saxony, 09116, Germany

  • Klinikum Nuernberg, Klinik fuer Innere Medizin 5, Abteilung Onkologie/Haematologie

    Nuremberg, Bavaria, 90419, Germany

  • Klinikum rechts der Isar der TU Muenchen AöR, Klinik und Poliklinik fuer Innere Medizin III

    Munich, Bavaria, 81675, Germany

  • Marien Hospital Duesseldorf GmbH, Klinik fuer Onkologie/Haematologie und Palliativmedizin

    Düsseldorf, North Rhine-Westphalia, 40479, Germany

  • Medizinische Hochschule Hannover, Klinik fuer Haematologie, Haemostaseologie, Onkologie und Stammzelltransplantation

    Hanover, Lower Saxony, 30625, Germany

  • Thoraxklinik Heidelberg gGmbH, Studienzentrum Thoraxonkologie

    Heidelberg, Baden-Wurttemberg, 69126, Germany

  • Universitaet Leipzig, Universitaeres Krebszentrum Leipzig (UCCL)

    Leipzig, Saxony, 04103, Germany

  • Universitaetsklinikum C. - G. - Carus Dresden, Technische Universitaet Dresden AöR, NCT/UCC Early Clinical Trial Unit

    Dresden, Saxony, 01307, Germany

  • Universitaetsklinikum Erlangen AöR, Interdisciplinary Clinical Trial Unit with ECTU

    Erlangen, Bavaria, 91054, Germany

  • Universitaetsklinikum Freiburg, Zentralklinikum, Klinik fuer Innere Medizin I

    Freiburg im Breisgau, Baden-Wurttemberg, 79106, Germany

  • Universitaetsklinikum Heidelberg AöR, Nationales Zentrum fuer Tumorkrankheiten

    Heidelberg, Baden-Wurttemberg, 69120, Germany

  • Universitaetsklinikum Muenster AöR, Medizinische Klinik A

    Münster, North Rhine-Westphalia, 48149, Germany

  • Universitaetsklinikum Regensburg AöR, Klinik fuer Innere Medizin 3

    Regensburg, Bavaria, 93053, Germany

  • Universitaetsklinikum Schleswig- Holstein, Campus Kiel, Medizinische Klinik II Haematologie und Onkologie, Karl-Lennert Tumorzentrum

    Kiel, Schleswig-Holstein, 24105, Germany

  • Universitaetsklinikum Tuebingen AöR, Comprehensive Cancer Center Tuebingen

    Tübingen, Baden-Wurttemberg, 72076, Germany

  • Universitaetsklinikum Ulm AöR, ECTU-Early clinical Trials Unit Universitaetsklinikum Ulm Comprehensive Cancer Center Ulm_CCCU

    Ulm, Baden-Wurttemberg, 89081, Germany

  • Universitaetsklinikum Wuerzburg AöR, Interdisziplinaeres Studienzentrum mit ECTU

    Würzburg, Bavaria, 97078, Germany

  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR, III. Medizinische Klinik

    Mainz, Rhineland-Palatinate, 55131, Germany

  • Universitätsklinikum Bonn AöR, Medizinische Klinik IIII

    Bonn, North Rhine-Westphalia, 53127, Germany